Laurion Capital Management’s Xilio Therapeutics XLO Stock Holding History

Laurion Capital Management’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,346	Closed	-$64.3K	–	650
2023 Q4	$64.3K	Sell	8,346 -1,601	-16%	-$31.7K	﹤0.01%	448
2023 Q3	$294K	Sell	9,947 -260	-3%	-$9.7K	﹤0.01%	410
2023 Q2	$374K	Hold	10,207	–	–	﹤0.01%	438
2023 Q1	$454K	Hold	10,207	–	–	﹤0.01%	348
2022 Q4	$384K	Hold	10,207	–	–	﹤0.01%	362
2022 Q3	$416K	Hold	10,207	–	–	﹤0.01%	409
2022 Q2	$417K	Buy	+10,207	New	+$540K	0.01%	349

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Laurion Capital Management's XLO Position: Q1 2024 in Review

Laurion Capital Management sold out of Xilio Therapeutics (XLO) in Q1 2024, closing a stake of 8,346 shares — an estimated $64.3K sold.

Laurion Capital Management first reported a position in XLO in Q2 2022 and held it in 7 quarters. The position peaked at $454K in Q1 2023. 30 funds tracked by Wall St. Rank hold XLO as of Q1 2024.

Laurion Capital Management reported no remaining Xilio Therapeutics position as of Q1 2024 after selling out during the quarter.
Laurion Capital Management sold 8,346 Xilio Therapeutics shares in Q1 2024, an estimated $64.3K.
Laurion Capital Management first reported a position in Xilio Therapeutics in Q2 2022 and held it in 7 quarters.
Laurion Capital Management's Xilio Therapeutics position peaked at $454K in Q1 2023.
30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.